Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria

• Status: Completed
• Trial end date: 2017-03-07
• Target enrollment: 0
• Participant gender: All

Summary

The disparity between supply and demand for organs has stimulated the development of strategies to increase the availability of kidney grafts. Such strategy involves the use of kidneys with expanded donor criteria (EDC). This is a study initiated by the investigator, open, prospective, randomized, single center designed to compare the safety and efficacy of two immunosuppressive regimens based on thymoglobulin, tacrolimus and everolimus versus thymoglobulin, tacrolimus and mycophenolate sodium in renal transplant recipients with donor criteria expanded.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Helio Tedesco Silva Junior
• Collaborators: Novartis; Sanofi
• Treatments: Antilymphocyte Serum; Everolimus; Mycophenolate mofetil; Mycophenolic Acid; Prednisone; Sirolimus; Tacrolimus; Thymoglobulin

Criteria

Inclusion Criteria:

• Adults (> 18 years) candidates to renal transplant with expanded criteria deceased donors;

• Low risk of acute rejection, defined as first kidney transplant recipients and Panel Reactive Antibody (PRA) <50%.

• Signature of the informed consent form (ICF)

Exclusion Criteria:

• Patients receiving immunosuppressive therapy before transplantation;

• Patients who have received an investigational drug within last 30 days;

• Patients with a known contraindication to the administration of an anti-thymocyte globulin;

• Patients with a positive test for human immunodeficiency virus (HIV);

• Patients who had cancer (except non-melanoma skin cancer) within last two years;

• Pregnant women, breastfeeding women, and women of childbearing potential unwilling to use condoms or oral contraceptives will be excluded;

• Patients with any Panel Reactive Antibody (PRA) equal to or higher than 50%, class I or class II, will also be excluded;

• Patients with positive test for parasites (protozoa and helminths).